https://scholars.lib.ntu.edu.tw/handle/123456789/568002
標題: | Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination | 作者: | CHUN-YI LU BOR-LUEN CHIANG Chi W.-K. MEI-HWEI CHANG YEN-HSUAN NI Hsu H.-M. Twu S.-J. Su I.-J. LI-MIN HUANG Lee C.-Y. |
公開日期: | 2004 | 卷: | 40 | 期: | 6 | 起(迄)頁: | 1415-1420 | 來源出版物: | Hepatology | 摘要: | Neonatal immunization with hepatitis B (HB) vaccine is highly effective; however, more needs to be learned about the duration of protection and indications for boosters. We measured antibody to HB core antigen (anti-HBc), HB surface antigen (HBsAg), and pre- and postbooster titers of HBsAg antibody (anti-HBs) 15 years after primary neonatal immunization with plasma-derived HB vaccines in 2 cohorts of 15-year-old children. Group A consisted of 78 children who were born to HB e antigen-positive HBsAg carrier mothers and had developed protective levels of anti-HBs antibodies (?10 mIU/mL) following HB immunization. Group B consisted of 113 apparently healthy children whose anti-HBs titers after vaccination were unknown. Anti-HBs was undetectable (antibody titer < 10 mIU/mL) in 29.9% in group A and 62.4% in group B (P < .001). Anti-HBc was detected in 33.3 % in group A and 4.4 % in group B (P < .001). After a single booster dose of HB vaccine, 2.7% in group A and 3.3% in group B remained anti-HBs-negative. A blunted serological response was noted in approximately 20% in both groups. One HBsAg carrier was detected in group A (1.3%) and 4 in group B (3.5%). Fifteen years after neonatal immunization with plasma-derived HB vaccine, a large proportion of children exhibited waning immunity. This poses the risk of breakthrough infection. A single booster augmented the serological response to the vaccine in most but not all subjects. In conclusion, our findings suggest that one or more booster immunizations are needed in seronegative subjects by at least 15 years following neonatal immunization with plasma-derived HB vaccine. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-10644244357&doi=10.1002%2fhep.20490&partnerID=40&md5=c75983a3032faa278778fc4738ee7342 https://scholars.lib.ntu.edu.tw/handle/123456789/568002 |
ISSN: | 0270-9139 | DOI: | 10.1002/hep.20490 | SDG/關鍵字: | hepatitis B vaccine; membrane antigen; adolescent; antibody titer; article; clinical trial; cohort analysis; controlled clinical trial; controlled study; female; hepatitis B; human; immunization; major clinical study; male; priority journal; risk assessment; serology; Adolescent; Adult; Female; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Vaccines; Humans; Immunization, Secondary; Infant, Newborn; Male; Mothers; Risk Factors; Treatment Failure |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。